Priority-driven Collaborative Cancer Research funding passes $110m

The Minister for Health and Aged Care, Sussan Ley, and Cancer Australia announced a further $10.39 million in funding for cancer research through Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).

Page last updated: 12 December 2016

PDF printable version of Priority-driven Collaborative Cancer Research funding passes $110m (PDF 371 KB)

The Hon Sussan Ley MP
Minister for Health and Aged Care
Minister for Sport

Australian Government
Cancer Australia


Joint Media Release


12 December 2016

The Minister for Health and Aged Care, Sussan Ley, and Cancer Australia today announced a further $10.39 million in funding for cancer research through Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS).

Minister Ley said that the 2016 round of grants pushed the amount invested in the Scheme past the $110 million milestone since its inception in 2007.

“The PdCCRS fosters collaboration in cancer research to improve outcomes and this year the Federal Government, through Cancer Australia, will invest $5.54 million with an additional $4.85 million contributed by funding partners to support 28 new research projects,” she said.

“The 2016 cancer research projects cover a range of cancer research from biological research to prevention, precision treatment, palliative care and quality of life.”

Cancer Australia CEO, Dr Helen Zorbas AO, said: “The PdCCRS provides an innovative national approach to funding cancer research across identified priority areas, bringing together government and non-government funding partners to maximise investment.”

This year's successful applications include research into reprogramming the tumour microenvironment for the treatment of pancreatic cancer; improving the precision of lung cancer radiotherapy; use of aspirin to treat colorectal cancer; improving the cure rates of childhood brain cancer; improving natural killer cell responses to immunotherapy in haematological cancers; new therapeutic targets for breast cancer; behaviour change techniques to help Indigenous pregnant women quit smoking; novel approaches to screening for people at high risk of cancer; and modifying the immune response to melanoma.

The successful grants in the 2016 round of the PdCCRS are funded by Cancer Australia with funding partners the Australasian Sarcoma Study Group, Cancer Council Australia, Cancer Council NSW, Cure Cancer Australia, National Breast Cancer Foundation and The Kids’ Cancer Project.

Cancer Australia collaborated with the National Health and Medical Research Council in the assessment of the research grant applications.

Further details of successful grant applications in the 2016 round of Cancer Australia’s PdCCRS can be found on the Cancer Australia website.

Media enquiries:
Minister Ley: Randal Markey (02) 6277 7220|0417 318 620.
Cancer Australia: Lisa Cuthbertson (02) 9357 9401 | 0438 209 833.


Cancer Australia is pleased to announce the successful applicants in the 2016 Round of the Priority-driven Collaborative Cancer Research Scheme. These include:


Agar, Meera
University of Technology Sydney
Randomised double blind placebo controlled phase III trial of oral melatonin for the prevention of delirium in hospitalised advanced cancer patients
Funded by Cancer Australia

Batra, Jyotsna
Queensland University of Technology
Functional and mechanistic characterisation of a novel LncRNA at chromosomal locus 5p15 in prostate cancer
Funded by Cure Cancer Australia

Cao, Yuan
Peter MacCallum Cancer Centre
Targeting matrix metalloproteinase-12 (MMP12) promotes an immune response against breast cancer
Funded by Cure Cancer Australia

Carter, Daniel
Children's Cancer Institute
Targeting FACT to inhibit MYCN-driven transcription in neuroblastoma
Co-funded by Cancer Australia and The Kids’ Cancer Project

Castano-Rodriguez, Natalia
University of NSW
The role of autophagy in gastric carcinogenesis
Funded by Cure Cancer Australia

Deans, Andrew
St Vincent’s Institute of Medical Research
Are FANCC and FANCM breast cancer predisposition genes?
Funded by the National Breast Cancer Foundation

D'Souza, Rochelle
QIMR Berghofer Medical Research Institute
Understanding the tumour suppressive function of ephrin A5 signalling in adult brain cancer
Funded by Cure Cancer Australia

Gould, Gillian
University of Newcastle
Assessing Behaviour Change Techniques for Indigenous Pregnant Smokers attending Aboriginal Medical Services - a nested study in a cluster Randomised Controlled Trial
Co-funded by Cancer Australia and Cure Cancer Australia

Guillerey, Camille
QIMR Berghofer Medical Research Institute
Improving Natural Killer cell responses to immunotherapy in haematological cancers
Co-funded by Cancer Australia and Cure Cancer Australia

Hovey, Elizabeth
Prince of Wales Hospital
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma: the CODEL trial
Co-funded by Cancer Australia and Cancer Council NSW

Lane, Steven
QIMR Berghofer Medical Research Institute
Dnmt3a loss contributes to disease progression in myeloproliferative neoplasm
Co-funded by Cancer Australia and Cure Cancer Australia

Lee, Gary
University of WA
FGF-Receptor Antagonist in Mesothelioma (FRAME) Study: A Phase II Clinical Trial
Funded by Cancer Australia

Lim, Su Yin
Macquarie University
Differential effects of MAPK inhibition on immune activity determine melanoma response
Co-funded by Cancer Australia and Cure Cancer Australia

Lock, Richard
Children's Cancer Institute
Reversing glucocorticoid resistance in paediatric acute lymphoblastic leukaemia - a novel epigenetic mechanism linked to lymphocyte-specific chromatin conformation
Co-funded by Cancer Australia and The Kids’ Cancer Project

Mielke, Lisa
Walter & Eliza Hall Institute of Medical Research
Transcriptional control of IL-17 producing T cells in gastrointestinal cancers.
Co-funded by Cancer Australia and Cure Cancer Australia

Morton, Rachel
University of Sydney
Computed tomography (CT) and positron emission tomography (PET)/CT surveillance imaging in asymptomatic Stage III melanoma patients - a prospective cohort study of clinical benefit and economic implications
Funded by Cancer Australia

Naylor, Matthew
University of Sydney
Targeting ACC1 as a novel therapeutic for the treatment of breast cancer
Funded by the National Breast Cancer Foundation

O'Brien, Ricky
University of Sydney
High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management
Funded by Cancer Australia

Phillips, Phoebe
University of NSW
Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer
Co-funded by Cancer Australia and Cancer Council Australia

Sahni, Sumit
University of Sydney
Molecular Role of the AMPK-Dependent Pathway in the Activity of Thiosemicarbazones Against Pancreatic Cancer.
Funded by Cure Cancer Australia

Segelov, Eva
University of NSW
ASCOLT: Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Trial
Co-funded by Cancer Australia and Cancer Council NSW

Sharbeen, George
Lowy Cancer Research Centre
MutY-Homolog is a Potential Therapeutic Target for Pancreatic Cancer
Funded by Cure Cancer Australia

Sieber, Oliver
The Walter and Eliza Hall Institute of Medical Research
Development of a Clinico-Molecular Colon Cancer Nomogram for personalisation of adjuvant chemotherapy in the Australian population
Funded by Cancer Australia

Sjoquist, Katrin
NHMRC Clinical Trials Centre
Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations
Co-funded by Cancer Australia and the National Breast Cancer Foundation

Souza-Fonseca-Guimaraes, Fernando
Walter & Eliza Hall Institute of Medical Research
Targeting suppressive TGF-beta to enhance innate lymphoid cell response against melanoma
Funded by Cure Cancer Australia

Taylor, Natalie
Macquarie University
Hide and seek with hereditary cancer: Improving detection of colorectal cancer patients with a high risk of Lynch syndrome
Funded by Cancer Australia

Thomas, David
Garvan Institute of Medical Research
A surveillance protocol for people at high risk of cancer using whole body magnetic resonance
Funded by the Australasian Sarcoma Study Group

Ziegler, David
Sydney Children's Hospital
Synthetic retinoid therapy for Diffuse Intrinsic Pontine Gliomas
Co-funded by Cancer Australia, Cancer Council NSW and The Kids’ Cancer Project

View by date:

Top of Page